通关藤口服液治疗肺癌合并慢性支气管炎回顾性研究  

Tongguanteng Oral Liquid(通关藤口服液)in Treatment of Lung Cancer Complicated with Chronic Bronchitis:A Retrospective Analysis

作　　者：隋博文[1] 梅婷婷 刘咏菲 闫珺[1] SUI Bowen;MEI Tingting;LIU Yongfei;YAN Jun(The First Affiliated Hospital of Heilongjiang University of Chinese Medicine,Harbin 150040,Heilongjiang,China;Heilongjiang University of Chinese Medicine,Harbin 150006,Heilongjiang,China)

机构地区：[1]黑龙江中医药大学附属第一医院,黑龙江哈尔滨150040 [2]黑龙江中医药大学,黑龙江哈尔滨150006

出　　处：《辽宁中医杂志》2024年第7期57-60,共4页Liaoning Journal of Traditional Chinese Medicine

基　　金：第五批全国中医临床优秀人才研修项目(国中医药人教函〔2022〕1号);黑龙江省教育厅科学技术研究项目(GY2019YF0210);黑龙江省博士后基金(LBH-Z18251);黑龙江省中医药科研项目(ZHY2022-155)。

摘　　要：目的 分析通关藤口服液对肺癌合并慢性支气管炎患者临床疗效的影响。方法 采用回顾性研究方法,收集2018年1月—2020年2月黑龙江中医药大学附属第一医院肿瘤科门诊治疗的38例肺癌合并慢性支气管炎患者的临床资料,根据用药情况分为通关藤组19例和脾氨肽组19例。其中,通关藤组予通关藤口服液治疗,脾氨肽组予脾氨肽口服冻干粉治疗。比较两组患者治疗后的CAT评分、中医证候(咳嗽、咳痰、喘息)评分、C-反应蛋白(CRP)、中性粒细胞计数/淋巴细胞计数比值(NLR)、治疗后1年内慢性支气管炎急性加重次数。结果 治疗后,两组患者CAT评分、中医证候(咳嗽、咳痰、喘息)评分、CRP、NLR均显著降低(P<0.05)。组间相比,通关藤组CAT评分、咳嗽和喘息评分、CRP、NLR均低于脾氨肽组(P<0.05)。通关藤组治疗后1年内慢性支气管炎急性加重次数为(1.21±0.89)次,少于脾氨肽组的(2.84±1.66)次(P<0.05)。结论 通关藤口服液可以显著改善肺癌合并慢性支气管炎患者咳嗽、喘息症状,减少慢性支气管炎急性加重次数,可能与改善机体炎症状态有关。Objective To analyze the effect of Tongguanteng Oral Liquid(通关藤口服液)in the treatment of lung cancer complicated with chronic bronchitis.Methods A retrospective study was adopted.From January 2018 to February 2020,the clinical data of 38 patients with lung cancer complicated with chronic bronchitis in the first affiliated hospital of Heilongjiang University of Chinese Medicine was collected.According to the drug use,the patients were divided into the Tongguanteng group(19 cases)who used Tongguanteng Oral Liquid and spleen aminopeptide group(19 cases)who use Spleen Aminopeptide Oral Lyophilized Powder.The CAT score,the scores of TCM syndromes(cough,expectoration,wheezing),CRP,NLR and the number of acute exacerbations of chronic bronchitis in 1 year after treatment were compared between the two groups.Results After treatment,the CAT score,the scores of TCM syndromes,the levels of CRP and NLR decreased in both groups(P<0.05).Compared with those in the spleen aminopeptide group,the CAT score,the scores of cough and wheezing,the levels of CRP and NLR were lower(P<0.05).The number of acute exacerbations of chronic bronchitis in the follow-up patients within 1 year was(1.21±0.89)times in the Tongguanteng group,which was less than that of the spleen aminopeptide group[(2.84±1.66)times](P<0.05).Conclusion For patients with lung cancer combined with chronic bronchitis,Tongguanteng Oral Liquid can significantly improve their symptoms of cough and wheeze,and reduce the times of acute exacerbation of chronic bronchitis,it might be related to the effect of Tongguanteng oral liquid on improving the inflammatory state of the body.

关 键 词：通关藤口服液 肺癌 慢性支气管炎 回顾性分析 

分 类 号：R273[医药卫生—中西医结合]